Ocular manifestations of systemic disease

Antineutrophil cytoplasmic antibody-associated vasculitis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose of review: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) may be localized or systemic, and can involve the eyes. This review presents the major disease features and treatments of these forms of systemic vasculitis. RECENT FINDINGS: It is increasingly recognized that ocular disease in AAV can occur in the absence of systemic disease, and that in limited eye disease the ANCA is frequently undetected. Ocular disease in AAV can take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis. Management of eye disease in ANCA-associated vasculitis includes local anti-inflammatory and moisturizing therapies, local and systemic glucocorticosteroid therapies. Systemic therapies are highly effective for the management of organ involvement of AAV including eye disease, and include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate. The results of recent, randomized, clinical trials have demonstrated the efficacy of a new tool in the therapeutic armamentarium for AAV, the use of B-cell-depleting therapy with rituximab. SUMMARY: Ocular disease in AAV can occur in isolation or more commonly as a manifestation of systemic disease. With recent advances in treatment, the organ and overall life expectancy of patients suffering from AAV has markedly improved.

Original languageEnglish (US)
Pages (from-to)489-495
Number of pages7
JournalCurrent Opinion in Ophthalmology
Volume22
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Eye Manifestations
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antineutrophil Cytoplasmic Antibodies
Eye Diseases
Vasculitis
Therapeutics
Orbital Pseudotumor
Scleritis
Mycophenolic Acid
Retinitis
Systemic Vasculitis
Keratitis
Azathioprine
Cell- and Tissue-Based Therapy
Life Expectancy
Methotrexate
Cyclophosphamide
B-Lymphocytes
Anti-Inflammatory Agents
Randomized Controlled Trials

Keywords

  • antineutrophil cytoplasmic antibody associated vasculitis
  • Churg-Strauss vasculitis
  • eye disease
  • granulomatosis with polyangiitis
  • treatment

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{5ef0e8c27a2842788c8a90901a5baca2,
title = "Ocular manifestations of systemic disease: Antineutrophil cytoplasmic antibody-associated vasculitis",
abstract = "Purpose of review: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) may be localized or systemic, and can involve the eyes. This review presents the major disease features and treatments of these forms of systemic vasculitis. RECENT FINDINGS: It is increasingly recognized that ocular disease in AAV can occur in the absence of systemic disease, and that in limited eye disease the ANCA is frequently undetected. Ocular disease in AAV can take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis. Management of eye disease in ANCA-associated vasculitis includes local anti-inflammatory and moisturizing therapies, local and systemic glucocorticosteroid therapies. Systemic therapies are highly effective for the management of organ involvement of AAV including eye disease, and include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate. The results of recent, randomized, clinical trials have demonstrated the efficacy of a new tool in the therapeutic armamentarium for AAV, the use of B-cell-depleting therapy with rituximab. SUMMARY: Ocular disease in AAV can occur in isolation or more commonly as a manifestation of systemic disease. With recent advances in treatment, the organ and overall life expectancy of patients suffering from AAV has markedly improved.",
keywords = "antineutrophil cytoplasmic antibody associated vasculitis, Churg-Strauss vasculitis, eye disease, granulomatosis with polyangiitis, treatment",
author = "Jean Schmidt and Pulido, {Jose S} and Matteson, {Eric Lawrence}",
year = "2011",
month = "11",
doi = "10.1097/ICU.0b013e32834bdfe2",
language = "English (US)",
volume = "22",
pages = "489--495",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Ocular manifestations of systemic disease

T2 - Antineutrophil cytoplasmic antibody-associated vasculitis

AU - Schmidt, Jean

AU - Pulido, Jose S

AU - Matteson, Eric Lawrence

PY - 2011/11

Y1 - 2011/11

N2 - Purpose of review: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) may be localized or systemic, and can involve the eyes. This review presents the major disease features and treatments of these forms of systemic vasculitis. RECENT FINDINGS: It is increasingly recognized that ocular disease in AAV can occur in the absence of systemic disease, and that in limited eye disease the ANCA is frequently undetected. Ocular disease in AAV can take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis. Management of eye disease in ANCA-associated vasculitis includes local anti-inflammatory and moisturizing therapies, local and systemic glucocorticosteroid therapies. Systemic therapies are highly effective for the management of organ involvement of AAV including eye disease, and include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate. The results of recent, randomized, clinical trials have demonstrated the efficacy of a new tool in the therapeutic armamentarium for AAV, the use of B-cell-depleting therapy with rituximab. SUMMARY: Ocular disease in AAV can occur in isolation or more commonly as a manifestation of systemic disease. With recent advances in treatment, the organ and overall life expectancy of patients suffering from AAV has markedly improved.

AB - Purpose of review: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) may be localized or systemic, and can involve the eyes. This review presents the major disease features and treatments of these forms of systemic vasculitis. RECENT FINDINGS: It is increasingly recognized that ocular disease in AAV can occur in the absence of systemic disease, and that in limited eye disease the ANCA is frequently undetected. Ocular disease in AAV can take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis. Management of eye disease in ANCA-associated vasculitis includes local anti-inflammatory and moisturizing therapies, local and systemic glucocorticosteroid therapies. Systemic therapies are highly effective for the management of organ involvement of AAV including eye disease, and include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate. The results of recent, randomized, clinical trials have demonstrated the efficacy of a new tool in the therapeutic armamentarium for AAV, the use of B-cell-depleting therapy with rituximab. SUMMARY: Ocular disease in AAV can occur in isolation or more commonly as a manifestation of systemic disease. With recent advances in treatment, the organ and overall life expectancy of patients suffering from AAV has markedly improved.

KW - antineutrophil cytoplasmic antibody associated vasculitis

KW - Churg-Strauss vasculitis

KW - eye disease

KW - granulomatosis with polyangiitis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=80054933608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054933608&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e32834bdfe2

DO - 10.1097/ICU.0b013e32834bdfe2

M3 - Article

VL - 22

SP - 489

EP - 495

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 6

ER -